<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025259</url>
  </required_header>
  <id_info>
    <org_study_id>AHOD0031</org_study_id>
    <secondary_id>NCI-2011-02069</secondary_id>
    <secondary_id>CDR0000068943</secondary_id>
    <secondary_id>COG-AHOD0031</secondary_id>
    <secondary_id>AHOD0031</secondary_id>
    <secondary_id>AHOD0031</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00025259</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease</brief_title>
  <official_title>A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying different chemotherapy regimens given with or
      without radiation therapy to compare how well they work in treating children with newly
      diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer
      cells from dividing so they stop growing or die. Giving the drugs in different combinations
      may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells.
      It is not yet known if chemotherapy is more effective with or without additional chemotherapy
      and/or radiation therapy in treating Hodgkin's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. To compare response-based therapy to standard therapy for intermediate risk Hodgkin
      disease.

      II. To determine whether involved field radiation therapy (IFRT) can be eliminated based upon
      early and complete response to multiagent chemotherapy.

      III. To determine whether the addition of an additional two cycles of chemotherapy (DECA) can
      improve outcome in those with a slow early response to standard chemotherapy.

      IV. To prospectively collect information on the individual prognostic significance of the
      following presenting factors: erythrocyte sedimentation rate, circulating levels of IL-10,
      each of the &quot;B&quot; symptoms - fever, night sweats, weight loss, nodal aggregate &gt; 6 cm, large
      mediastinal mass &gt; 1/3 thoracic diameter and number of involved nodal sites, histology,
      albumin, blood counts, sex and age.

      V. To study the reliability and utility of [18F] -Fluorodeoxyglucose (FDG) Imaging (PET
      scans) as an imaging modality in Hodgkin disease.

      VI. To determine the frequency and severity of late effects of therapy including thyroid
      dysfunction, infertility, cardiotoxicity, pulmonary toxicity and second malignant neoplasms.

      VII. To serve as the therapeutic companion to biology studies in Hodgkin disease and
      correlate those results with response to therapy, event free-survival and overall survival.

      OUTLINE: This is a randomized, multicenter study.

      ARM I (ALL PATIENTS-OFF THERAPY BEFORE CALLBACK-INDUCTION CHEMOTHERAPY [ABVE-PC]): Patients
      receive doxorubicin intravenously (IV) over 10-30 minutes on days 1-2, bleomycin sulfate IV
      over 10-20 minutes or subcutaneously (SC) and vincristine IV on days 1 and 8, etoposide IV
      over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide
      IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and
      continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21
      days for 2 courses in the absence of progressive disease. At the end of initial chemotherapy,
      patients undergo evaluation for response. Patients with less than 60% disease reduction are
      considered to have slow early response (SER). Patients with 60% or more disease reduction are
      considered to have rapid early response (RER).

      RER: Patients receive 2 additional courses of ABVE-PC chemotherapy. After completion of
      treatment, patients are randomized to 1 of 4 treatment arms.

      ARM II: Patients with sustained complete response (CR) undergo involved field radiation
      therapy (IFRT) approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a
      week.

      ARM III: Patients with sustained CR receive no further treatment.

      ARM IV: Patients with very good partial response (VGPR), partial response (PR) or stable
      disease (SD) undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5
      days a week.

      ARM V: Patients with progressive disease are taken off therapy and treated their physician's
      discretion.

      SER: Patients are randomized to 1 of 2 treatment arms.

      ARM VI: Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours,
      cytarabine IV over 3 hours on days 1-2, and receive 2 drops of dexamethasone ophthalmic
      solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12
      hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning
      on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2
      courses in the absence of disease progression or unacceptable toxicity. After these 2
      courses, patients then receive 2 additional courses of ABVE-PC chemotherapy.

      ARM VII: Patients receive 2 courses of ABVE-PC chemotherapy.

      In both SER arms, patients with sustained CR or PR undergo IFRT approximately 3 weeks after
      the last course of chemotherapy.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response Assessed by Modified RECIST Criteria</measure>
    <time_frame>Protocol therapy: the overall duration of which is: (n=1527) an average of 137.1 days, median 133.0 days, interquartile range: 101.0, 164.0 days.</time_frame>
    <description>Number of participants with complete response and very good partial response at the end of protocol therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 Non-hematologic Toxicity</measure>
    <time_frame>Protocol therapy: the overall duration of which is: (n=1684) an average of 137.3 days, median 133.0 days, interquartile range: 101.0, 164.0 days.</time_frame>
    <description>Occurrence of any grade 4 non-hematologic toxicity or grade 3 non-hematologic toxicity which doesn't respond to treatment within 7 days despite recommended therapy modification, or toxic death, which is any death primarily attributable to treatment. Grade 3 is defined to be severe or medically significant but not immediate life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 refers to toxicities with life-threatening consequences; urgent intervention indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Probability of overall survival which is defined as the time from study entry to death from any cause. Patients alive where censored at last contact.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1734</enrollment>
  <condition>Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma</condition>
  <condition>Childhood Mixed Cellularity Classical Hodgkin Lymphoma</condition>
  <condition>Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Childhood Nodular Sclerosis Classical Hodgkin Lymphoma</condition>
  <condition>Stage I Childhood Hodgkin Lymphoma</condition>
  <condition>Stage II Childhood Hodgkin Lymphoma</condition>
  <condition>Stage III Childhood Hodgkin Lymphoma</condition>
  <condition>Stage IV Childhood Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, and cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bleomycin Sulfate</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>Blanoxan</other_name>
    <other_name>BleMomycine</other_name>
    <other_name>Blenoxane</other_name>
    <other_name>Bleo-cell</other_name>
    <other_name>Bleo-S</other_name>
    <other_name>Bleocin</other_name>
    <other_name>Bleolem</other_name>
    <other_name>Bleomycin Sulfas</other_name>
    <other_name>Bleomycin Sulphate</other_name>
    <other_name>Blexane</other_name>
    <other_name>Oil Bleo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Involved-Field Radiation Therapy</intervention_name>
    <description>Undergo IFRT</description>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>IFRT</other_name>
    <other_name>Involved field radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate Liposome</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Patients off-therapy before callback-Induction only)</arm_group_label>
    <arm_group_label>Arm II (RER with CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm III (RER with CR [ABVE-PC])</arm_group_label>
    <arm_group_label>Arm IV (RER with less than CR [ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm V (RER with PD)</arm_group_label>
    <arm_group_label>Arm VI (SER [DECA, ABVE-PC, IFRT])</arm_group_label>
    <arm_group_label>Arm VII (SER [ABVE-PC, IFRT])</arm_group_label>
    <other_name>Marqibo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed, pathologically confirmed Hodgkin disease (all
             histologies) are eligible for this protocol if they meet the following clinical stage
             guidelines:

               -  All Stage IB regardless of bulk disease

               -  All Stage IIB regardless of bulk disease

               -  Stage IA only with bulk disease

               -  Stage IIA only with bulk disease

               -  All Stage IAE, IIAE regardless of bulk disease

               -  All Stage IIIA, IIIAE, IIIAS, IIIAE+S regardless of bulk disease

               -  All Stage IVA, IVAE regardless of bulk disease

          -  May not be staged by laparotomy alone

               -  Surgically staged patients must also have presurgical staging

          -  Bilirubin no greater than 1.5 times normal

          -  SGOT or SGPT less than 2.5 times normal

          -  Creatinine no greater than 1.5 times normal

          -  Creatinine clearance greater than 40 mL/min

          -  Radioisotope glomerular filtration rate greater than 70 mL/min

          -  Shortening fraction at least 27% by echocardiogram

          -  Ejection fraction at least 50% by MUGA

          -  No pathologic prolongation of QTc interval on 12-lead electrocardiogram

          -  FEV_1/FVC greater than 60% by pulmonary function test

          -  Pulse oximetry greater than 94%

          -  No evidence of dyspnea at rest

          -  No exercise intolerance

          -  Adequate venous access

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior chemotherapy

          -  At least 1 month since prior corticosteroids except prednisone for respiratory
             distress

          -  No prior radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Friedman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636-8762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalamazoo Center for Medical Studies</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Steven and Alexandra Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University/Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital-Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center-Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital/Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at Saint Francis</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Cancer Treatment Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T C Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center-Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital-King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center - Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic Children's Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital-Adelaide</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Child Health Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chedoke Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah Tikua</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1145</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group - Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="P3">
          <title>Arm III (RER With CR [ABVE-PC])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="P4">
          <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="P5">
          <title>Arm V (RER With PD)</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="P6">
          <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
          <description>Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, &amp; cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 &amp; 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 &amp; G-CSF SC beginning on day 3 &amp; continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
Bleomycin Sulfate: Given IV or SC
Cisplatin: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Dexamethasone: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Pre</description>
        </group>
        <group group_id="P7">
          <title>Arm VII (SER [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="381"/>
                <participants group_id="P3" count="382"/>
                <participants group_id="P4" count="571"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="153"/>
                <participants group_id="P7" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="292"/>
                <participants group_id="P3" count="301"/>
                <participants group_id="P4" count="457"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="101"/>
                <participants group_id="P7" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="78"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="30"/>
                <participants group_id="P7" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Arm III (RER With CR [ABVE-PC])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="B4">
          <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="B5">
          <title>Arm V (RER With PD)</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="B6">
          <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
          <description>Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, &amp; cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 &amp; 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 &amp; G-CSF SC beginning on day 3 &amp; continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
Bleomycin Sulfate: Given IV or SC
Cisplatin: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Dexamethasone: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Pre</description>
        </group>
        <group group_id="B7">
          <title>Arm VII (SER [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="381"/>
            <count group_id="B3" value="382"/>
            <count group_id="B4" value="571"/>
            <count group_id="B5" value="42"/>
            <count group_id="B6" value="153"/>
            <count group_id="B7" value="153"/>
            <count group_id="B8" value="1734"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="363"/>
                    <measurement group_id="B3" value="369"/>
                    <measurement group_id="B4" value="540"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="143"/>
                    <measurement group_id="B7" value="148"/>
                    <measurement group_id="B8" value="1649"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="5" upper_limit="20"/>
                    <measurement group_id="B2" value="14" lower_limit="2" upper_limit="21"/>
                    <measurement group_id="B3" value="14" lower_limit="3" upper_limit="21"/>
                    <measurement group_id="B4" value="15" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="B5" value="15" lower_limit="5" upper_limit="19"/>
                    <measurement group_id="B6" value="15" lower_limit="5" upper_limit="21"/>
                    <measurement group_id="B7" value="15" lower_limit="5" upper_limit="21"/>
                    <measurement group_id="B8" value="15" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="288"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="81"/>
                    <measurement group_id="B7" value="77"/>
                    <measurement group_id="B8" value="815"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="227"/>
                    <measurement group_id="B4" value="283"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B7" value="76"/>
                    <measurement group_id="B8" value="919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="306"/>
                    <measurement group_id="B4" value="487"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="127"/>
                    <measurement group_id="B7" value="134"/>
                    <measurement group_id="B8" value="1425"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="297"/>
                    <measurement group_id="B4" value="444"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="122"/>
                    <measurement group_id="B7" value="124"/>
                    <measurement group_id="B8" value="1348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="312"/>
                    <measurement group_id="B4" value="491"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="125"/>
                    <measurement group_id="B7" value="128"/>
                    <measurement group_id="B8" value="1469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kuwait</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bermuda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>French Polynesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <description>Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact.</description>
        <time_frame>5 years</time_frame>
        <population>Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
            <description>All patients-off therapy before callback-Induction only</description>
          </group>
          <group group_id="O2">
            <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
            <description>RER with Complete Response - IFRT (Standard Arm)</description>
          </group>
          <group group_id="O3">
            <title>Arm III (RER With CR [ABVE-PC])</title>
            <description>RER with Complete Response - no IFRT (Reduced Therapy Arm)</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
            <description>RER with less than Complete Response - IFRT</description>
          </group>
          <group group_id="O5">
            <title>Arm V (RER With PD)</title>
            <description>RER with Progressive Disease - Off Therapy</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
            <description>SER - randomized to DECAX2 + ABVE-PCX2 + IFRT</description>
          </group>
          <group group_id="O7">
            <title>Arm VII (SER [ABVE-PC, IFRT])</title>
            <description>SER - randomized to ABVE-PCX2 + IFRT</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact.</description>
          <population>Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
          <units>Probability of survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="571"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="153"/>
                <count group_id="O7" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.69" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.83" upper_limit="0.90"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.80" upper_limit="0.87"/>
                    <measurement group_id="O4" value="0.87" lower_limit="0.83" upper_limit="0.89"/>
                    <measurement group_id="O5" value="0.70" lower_limit="0.51" upper_limit="0.82"/>
                    <measurement group_id="O6" value="0.79" lower_limit="0.71" upper_limit="0.85"/>
                    <measurement group_id="O7" value="0.74" lower_limit="0.66" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Response Assessed by Modified RECIST Criteria</title>
        <description>Number of participants with complete response and very good partial response at the end of protocol therapy.</description>
        <time_frame>Protocol therapy: the overall duration of which is: (n=1527) an average of 137.1 days, median 133.0 days, interquartile range: 101.0, 164.0 days.</time_frame>
        <population>Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
            <description>All patients-off therapy before callback-Induction only</description>
          </group>
          <group group_id="O2">
            <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
            <description>RER with Complete Response - IFRT (Standard Arm)</description>
          </group>
          <group group_id="O3">
            <title>Arm III (RER With CR [ABVE-PC])</title>
            <description>RER with Complete Response - no IFRT ( Reduced Therapy Arm)</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
            <description>RER with less than Complete Response - IFRT</description>
          </group>
          <group group_id="O5">
            <title>Arm V (RER With PD)</title>
            <description>RER with Progressive Disease - Off Therapy</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
            <description>SER - randomized to DECAX2 + ABVE-PCX2 + IFRT</description>
          </group>
          <group group_id="O7">
            <title>Arm VII (SER [ABVE-PC, IFRT])</title>
            <description>SER - randomized to ABVE-PCX2 + IFRT</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response Assessed by Modified RECIST Criteria</title>
          <description>Number of participants with complete response and very good partial response at the end of protocol therapy.</description>
          <population>Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="571"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="153"/>
                <count group_id="O7" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="370"/>
                    <measurement group_id="O3" value="380"/>
                    <measurement group_id="O4" value="538"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="105"/>
                    <measurement group_id="O7" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 3 or 4 Non-hematologic Toxicity</title>
        <description>Occurrence of any grade 4 non-hematologic toxicity or grade 3 non-hematologic toxicity which doesn't respond to treatment within 7 days despite recommended therapy modification, or toxic death, which is any death primarily attributable to treatment. Grade 3 is defined to be severe or medically significant but not immediate life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 refers to toxicities with life-threatening consequences; urgent intervention indicated.</description>
        <time_frame>Protocol therapy: the overall duration of which is: (n=1684) an average of 137.3 days, median 133.0 days, interquartile range: 101.0, 164.0 days.</time_frame>
        <population>Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
            <description>All patients-off therapy before callback-Induction only</description>
          </group>
          <group group_id="O2">
            <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
            <description>RER with Complete Response - IFRT (Standard Arm)</description>
          </group>
          <group group_id="O3">
            <title>Arm III (RER With CR [ABVE-PC])</title>
            <description>RER with Complete Response - no IFRT ( Reduced Therapy Arm)</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
            <description>RER with less than Complete Response - IFRT</description>
          </group>
          <group group_id="O5">
            <title>Arm V (RER With PD)</title>
            <description>RER with Progressive Disease - Off Therapy</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
            <description>SER - randomized to DECAX2 + ABVE-PCX2 + IFRT</description>
          </group>
          <group group_id="O7">
            <title>Arm VII (SER [ABVE-PC, IFRT])</title>
            <description>SER - randomized to ABVE-PCX2 + IFRT</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3 or 4 Non-hematologic Toxicity</title>
          <description>Occurrence of any grade 4 non-hematologic toxicity or grade 3 non-hematologic toxicity which doesn't respond to treatment within 7 days despite recommended therapy modification, or toxic death, which is any death primarily attributable to treatment. Grade 3 is defined to be severe or medically significant but not immediate life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 refers to toxicities with life-threatening consequences; urgent intervention indicated.</description>
          <population>Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="571"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="153"/>
                <count group_id="O7" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="216"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="62"/>
                    <measurement group_id="O7" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Probability of overall survival which is defined as the time from study entry to death from any cause. Patients alive where censored at last contact.</description>
        <time_frame>5 years</time_frame>
        <population>Arm V (RER with PD), has been excluded as there were no deaths observed by the Time Frame of 5 years. Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
            <description>All patients-off therapy before callback-Induction only</description>
          </group>
          <group group_id="O2">
            <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
            <description>RER with Complete Response - IFRT (Standard Arm)</description>
          </group>
          <group group_id="O3">
            <title>Arm III (RER With CR [ABVE-PC])</title>
            <description>RER with Complete Response - no IFRT ( Reduced Therapy Arm)</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
            <description>RER with less than Complete Response - IFRT</description>
          </group>
          <group group_id="O5">
            <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
            <description>SER - randomized to DECAX2 + ABVE-PCX2 + IFRT</description>
          </group>
          <group group_id="O6">
            <title>Arm VII (SER [ABVE-PC, IFRT])</title>
            <description>SER - randomized to ABVE-PCX2 + IFRT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Probability of overall survival which is defined as the time from study entry to death from any cause. Patients alive where censored at last contact.</description>
          <population>Arm V (RER with PD), has been excluded as there were no deaths observed by the Time Frame of 5 years. Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</population>
          <units>Probability of survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="571"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.74" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.96" upper_limit="0.99"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.96" upper_limit="0.99"/>
                    <measurement group_id="O4" value="0.98" lower_limit="0.96" upper_limit="0.99"/>
                    <measurement group_id="O5" value="0.96" lower_limit="0.91" upper_limit="0.98"/>
                    <measurement group_id="O6" value="0.93" lower_limit="0.87" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious AE:
Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).
Other AE:
Eligible participants are analyzed and ineligible participants (n=22) are excluded from Arms I (n=14), II (n=1), III (n=0), IV (n=6), V (n=0), VI (n=1), and VII (n=0).</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Patients Off-therapy Before Callback-Induction Only)</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II (RER With CR [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="E3">
          <title>Arm III (RER With CR [ABVE-PC])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="E4">
          <title>Arm IV (RER With Less Than CR [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="E5">
          <title>Arm V (RER With PD)</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
        <group group_id="E6">
          <title>Arm VI (SER [DECA, ABVE-PC, IFRT])</title>
          <description>Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, &amp; cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 &amp; 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 &amp; G-CSF SC beginning on day 3 &amp; continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
Bleomycin Sulfate: Given IV or SC
Cisplatin: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Dexamethasone: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Pre</description>
        </group>
        <group group_id="E7">
          <title>Arm VII (SER [ABVE-PC, IFRT])</title>
          <description>Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
Bleomycin Sulfate: Given IV or SC
Cyclophosphamide: Given IV
Doxorubicin Hydrochloride: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Involved-Field Radiation Therapy: Undergo IFRT
Prednisone: Given orally
Vincristine Sulfate Liposome: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="571"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood antidiuretic hormone abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="341" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="334" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="497" subjects_at_risk="571"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="135" subjects_at_risk="153"/>
                <counts group_id="E7" subjects_affected="133" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="196" subjects_affected="196" subjects_at_risk="380"/>
                <counts group_id="E3" events="162" subjects_affected="162" subjects_at_risk="382"/>
                <counts group_id="E4" events="245" subjects_affected="245" subjects_at_risk="571"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="36"/>
                <counts group_id="E6" events="85" subjects_affected="85" subjects_at_risk="153"/>
                <counts group_id="E7" events="63" subjects_affected="63" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="380"/>
                <counts group_id="E3" events="35" subjects_affected="35" subjects_at_risk="382"/>
                <counts group_id="E4" events="57" subjects_affected="57" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="31" subjects_affected="31" subjects_at_risk="153"/>
                <counts group_id="E7" events="20" subjects_affected="20" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="111" subjects_affected="111" subjects_at_risk="380"/>
                <counts group_id="E3" events="99" subjects_affected="99" subjects_at_risk="382"/>
                <counts group_id="E4" events="128" subjects_affected="128" subjects_at_risk="571"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" events="45" subjects_affected="45" subjects_at_risk="153"/>
                <counts group_id="E7" events="31" subjects_affected="31" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="380"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="380"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="382"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="380"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="382"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="380"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E4" events="20" subjects_affected="20" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="380"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="382"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="71" subjects_affected="71" subjects_at_risk="380"/>
                <counts group_id="E3" events="61" subjects_affected="61" subjects_at_risk="382"/>
                <counts group_id="E4" events="79" subjects_affected="79" subjects_at_risk="571"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E6" events="26" subjects_affected="26" subjects_at_risk="153"/>
                <counts group_id="E7" events="16" subjects_affected="16" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood antidiuretic hormone abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="380"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="382"/>
                <counts group_id="E4" events="53" subjects_affected="53" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="24" subjects_affected="24" subjects_at_risk="153"/>
                <counts group_id="E7" events="17" subjects_affected="17" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="38"/>
                <counts group_id="E2" events="319" subjects_affected="319" subjects_at_risk="380"/>
                <counts group_id="E3" events="307" subjects_affected="307" subjects_at_risk="382"/>
                <counts group_id="E4" events="449" subjects_affected="449" subjects_at_risk="571"/>
                <counts group_id="E5" events="20" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E6" events="126" subjects_affected="126" subjects_at_risk="153"/>
                <counts group_id="E7" events="116" subjects_affected="116" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="152" subjects_affected="152" subjects_at_risk="380"/>
                <counts group_id="E3" events="119" subjects_affected="119" subjects_at_risk="382"/>
                <counts group_id="E4" events="167" subjects_affected="167" subjects_at_risk="571"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E6" events="98" subjects_affected="98" subjects_at_risk="153"/>
                <counts group_id="E7" events="55" subjects_affected="55" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="71" subjects_affected="71" subjects_at_risk="380"/>
                <counts group_id="E3" events="69" subjects_affected="69" subjects_at_risk="382"/>
                <counts group_id="E4" events="126" subjects_affected="126" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="50" subjects_affected="50" subjects_at_risk="153"/>
                <counts group_id="E7" events="31" subjects_affected="31" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="380"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="382"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="380"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="382"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="380"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="382"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="380"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="382"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="382"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="571"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="380"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="382"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="380"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="380"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

